Neuphoria Therapeutics Total Liabilities 2022-2024 | NEUP

Neuphoria Therapeutics total liabilities from 2022 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Neuphoria Therapeutics Total Liabilities 2022-2024 | NEUP

Neuphoria Therapeutics total liabilities from 2022 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$139.4B
Bristol Myers Squibb (BMY)$115.2B
Gilead Sciences (GILD)$114.5B
Vertex Pharmaceuticals (VRTX)$104.5B
CSL (CSLLY)$84.4B
Regeneron Pharmaceuticals (REGN)$78.6B
GSK (GSK)$70.4B
Argenex SE (ARGX)$37.4B
Alnylam Pharmaceuticals (ALNY)$30.1B
BioNTech SE (BNTX)$27.6B
Biogen (BIIB)$21.9B
Illumina (ILMN)$20.8B
BeiGene (ONC)$18B
Moderna (MRNA)$16.2B
Genmab (GMAB)$13.9B
Incyte (INCY)$13.4B
BioMarin Pharmaceutical (BMRN)$12.7B
Insmed (INSM)$12.5B
Sarepta Therapeutics (SRPT)$11.9B
Bio-Techne Corp (TECH)$11.4B
Exact Sciences (EXAS)$10.5B
Vaxcyte (PCVX)$10.4B
QIAGEN (QGEN)$10.2B
Swedish Orphan Biovitrum (BIOVF)$10.1B
Exelixis (EXEL)$9.7B
Bio-Rad Laboratories (BIO.B)$9.1B
Intra-Cellular Therapies (ITCI)$8.9B
Roivant Sciences (ROIV)$8.8B
Ascendis Pharma (ASND)$8.4B
Repligen (RGEN)$8B